Bristol-Myers Squibb Co (BMY) Expected to Announce Quarterly Sales of $5.19 Billion
Wall Street brokerages forecast that Bristol-Myers Squibb Co (NYSE:BMY) will post $5.19 billion in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Bristol-Myers Squibb’s earnings. The lowest sales estimate is $5.13 billion and the highest is $5.28 billion. Bristol-Myers Squibb posted sales of $4.93 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 5.3%. The firm is scheduled to report its next quarterly earnings results on Thursday, April 26th.
According to Zacks, analysts expect that Bristol-Myers Squibb will report full-year sales of $5.19 billion for the current year, with estimates ranging from $20.86 billion to $21.86 billion. For the next financial year, analysts forecast that the firm will post sales of $23.38 billion per share, with estimates ranging from $21.97 billion to $24.58 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. The company had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.63 EPS.
Shares of Bristol-Myers Squibb (NYSE:BMY) traded up $0.01 during trading hours on Thursday, hitting $62.70. 11,131,473 shares of the stock were exchanged, compared to its average volume of 8,430,000. The firm has a market cap of $102,620.00, a price-to-earnings ratio of 106.27, a P/E/G ratio of 1.95 and a beta of 1.08. Bristol-Myers Squibb has a 12 month low of $51.52 and a 12 month high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.
The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were paid a dividend of $0.40 per share. The ex-dividend date was Thursday, January 4th. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio is currently 271.19%.
In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Theodore R. Samuels II purchased 4,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, December 15th. The stock was purchased at an average price of $62.30 per share, with a total value of $249,200.00. Following the transaction, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Delphi Private Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $108,000. Massey Quick Simon & CO. LLC lifted its position in shares of Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 1,492 shares in the last quarter. Horan Capital Advisors LLC. purchased a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at approximately $122,000. NuWave Investment Management LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $119,000. Finally, Tradewinds Capital Management LLC lifted its position in shares of Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 500 shares in the last quarter. Institutional investors and hedge funds own 69.70% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.